DNA methylation analysis with methylation‐sensitive high‐resolution melting (MS‐HRM) reveals gene panel for glioma characteristics
Open Access
- 11 August 2020
- journal article
- research article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 26 (12) , 1303-1314
Abstract
Introduction: Local DNA hypermethylation is a potential source of cancer biomarkers. While the evaluation of single gene methylation has limited value, their selected panel may provide better information.Aims: This study aimed to analyze the promoter methylation level in a 7‐gene panel in brain tumors and verifies the usefulness of methylation‐sensitive high‐resolution melting (MS‐HRM) for this purpose.Methods: Forty‐six glioma samples and one non‐neoplastic brain sample were analyzed by MS‐HRM in terms of SFRP1, SFRP2, RUNX3, CBLN4, INA, MGMT, and RASSF1A promoter methylation. The results were correlated with patients’ clinicopathological features.Results: DNA methylation level of all analyzed genes was significantly higher in brain tumor samples as compared to non‐neoplastic brain and commercial, unmethylated DNA control. RASSF1A was the most frequently methylated gene, with statistically significant differences depending on the tumor WHO grade. Higher MGMT methylation levels were observed in females, whereas the levels of SFRP1 and INA promoter methylation significantly increased with patients’ age. A positive correlation of promoter methylation levels was observed between pairs of genes, for example, CBLN4 and INA or MGMT and RASSF1A.Conclusions: Our 7‐gene panel of promoter methylation can be helpful in brain tumor diagnosis or characterization, and MS‐HRM is a suitable method for its analysis.Keywords
Funding Information
- Poznań University of Medical Sciences
This publication has 64 references indexed in Scilit:
- Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patientsJournal of Applied Genetics, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastomaNeuro-Oncology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Quantitation of DNA methylation by melt curve analysisBMC Cancer, 2009
- Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?BMC Cancer, 2009
- A new approach to primer design for the control of PCR bias in methylation studiesBMC Research Notes, 2008
- Development of a broad-host-range sacB-based vector for unmarked allelic exchangeBMC Research Notes, 2008
- Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylationNucleic Acids Research, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005